Journal of Ilam University of Medical Sciences
مجله دانشگاه علوم پزشکی ایلام
J. Ilam Uni. Med. Sci.
Medical Sciences
http://sjimu.medilam.ac.ir
96
journal96
1563-4728
2588-3135
doi
fa
jalali
1401
9
1
gregorian
2022
12
1
30
6
online
1
fulltext
fa
اثر پیشگیریکنندۀ تجویز موضعی محیط کشت بهینه با سلولهای بنیادی مزانشیمی (MSC-CM) انسانی بر نوع شبه درماتیت آتوپیک ناشی از DNCB در موش
The Preventive Effect of Topical Administration of Human Mesenchymal Stem Cells-Conditioned Medium (MSC-CM) on DNCB-Induced Atopic Dermatitis-Like Model in Mice
فیزیولوژی جانوری
animal physiology
پژوهشي
Research
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:"Calibri",sans-serif"><b><span lang="FA" style="font-size:9.0pt"><span style="font-family:"B Zar""><span style="color:black"><span style="letter-spacing:.1pt">مقدمه:</span></span></span></span></b> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">درماتیت آتوپیک (</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">AD</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">) بیماری پوستی التهابی مزمنی است که درمان کافی برای آن وجود ندارد. سلولهای بنیادی مزانشیمی پیش از این نیز برای درمان بیماریهای التهابی استفاده شدهاند.</span></span> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">در مطالعۀ حاضر، اثر تجویز محیط کشـت بهینـه (</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">MSC-CM</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">) با سلولهای بنیادی مزانشیمی انسان بر نوع </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">AD</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> و ارتباط آن با درد مرکزی، سطح فاکتورهای استرس اکسیداتیو و التهابی در پوست بررسی گردید.</span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:"Calibri",sans-serif"><b><span lang="FA" style="font-size:9.0pt"><span style="font-family:"B Zar""><span style="color:black"><span style="letter-spacing:.1pt">مواد و روش ها:</span></span></span></span></b> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">گونۀ </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">AD</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> توسط تجویز موضعی محلول حاوی ترکیب 2،4 دی نیترو کلروبنزن 2 درصد (</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">DNCB</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">) روی پوست پشت و گوش موشها ایجاد شد. موشها </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">MSC-CM</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> و کرم بتامتازون را بهعنوان کنترل مثبت، سه بار در روز به مدت 2 هفته بهصورت موضعی دریافت کردند. سطح اینترلوکین-4 (</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">IL-4</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">) و مالون</span></span> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">دی آلدئید (</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">MDA</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">) پوست در همۀ گروهها به روش </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">ELISA</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar""> اندازهگیری گردید. تغییر در آستانۀ درد توسط آزمون پس کشیدن دم ارزیابی شد. تغییرات بافتی پوست بدن و گوش پس از رنگآمیزی بافتی هماتوکسیلین-ائوزین ارزیابی گردید و تعداد ماستسلها در برشهای رنگآمیزی</span></span> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">شده با تولوئیدن بلو شمارش شدند.</span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:"Calibri",sans-serif"><b><span lang="FA" style="font-size:9.0pt"><span style="font-family:"B Zar""><span style="color:black"><span style="letter-spacing:-.1pt">یافتهها:</span></span></span></span></b> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">تجویز موضعی </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">MSC-CM</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> و بتامتازون توانست درد، التهاب و افزایش ضخامت درم در پوست پشت و لالۀ گوش و همچنین نفوذ سلولهای ماست در پوست گروههای درمان شده با </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">DNCB</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> را کاهش دهد؛ همچنین </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">MSC-CM</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> مشابه با بتامتازون، سبب کاهش سطح </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">IL-4</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> و </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">MDA</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> پوست گروههای دریافتکنندۀ </span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">DNCB</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> شد.</span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:"Calibri",sans-serif"><b><span lang="FA" style="font-size:9.0pt"><span style="font-family:"B Zar""><span style="color:black"><span style="letter-spacing:-.1pt">بحث و نتیجهگیری:</span></span></span></span></b> <span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">افزایش سطح</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif"> IL-4 </span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">و پراکسیداسیون لیپیدی نقش مهمی در ایجاد ضایعات شبه</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif"> AD </span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">در پوست موش در مدل</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif"> DNCB</span></span><span style="font-size:9.0pt"><span style="font-family:"B Zar""> ایفا میکند و کاربرد موضعی</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif"> MSC-CM </span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">عامل درمانی بالقوه ای برای</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif"> AD </span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar"">است</span></span><span dir="LTR" style="font-size:8.0pt"><span style="font-family:"Times New Roman",serif">.</span></span><span lang="AR-SA" style="font-size:9.0pt"><span style="font-family:"B Zar""></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span calibri="" style="font-family:"><span style="font-size:10.0pt"><span style="line-height:115%"><span arial="" style="font-family:"><span style="color:black"></span></span></span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:"Calibri",sans-serif"><b><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><span style="letter-spacing:-.2pt">Introduction:</span></span></span></span></b> <span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">Atopic dermatitis (AD) is a chronic inflammatory skin disease for which there is no adequate treatment. Mesenchymal stem cells have already been used to treat inflammatory diseases. The present study investigated the effect of the administration of human mesenchymal stem cells-conditioned medium (MSC-CM) on the AD model and its relationship with central pain, the level of oxidative, and inflammatory stress factors in the skin.</span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:"Calibri",sans-serif"><b><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><span style="letter-spacing:-.2pt">Material & Methods:</span></span></span></span></b> <span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">The AD model was established by topical administration of a 2% 4,2-dinitrochlorobenzene (DNCB) solution on the dorsal and ear skin of mice. Mice received topical MSC-CM and betamethasone ointment as a positive control three times a day for 2 weeks. Skin interleukin-4 (IL-4) and malondialdehyde (MDA) levels were measured by the ELISA method in all groups. Changes in nociception were assessed by the tail flick test. Histological changes in the body and ear skins were evaluated after hematoxylin-eosin (H&E) staining, and mast cells number in toluidine blue-stained sections were counted in this study.</span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:"Calibri",sans-serif"><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">(Ethic code: </span></span><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">IR.SHAHED.REC.1399.095</span></span><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">)</span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:"Calibri",sans-serif"><b><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><span style="letter-spacing:-.2pt">Findings:</span></span></span></span></b> <span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">Topical administration of MSC-CM and betamethasone was able to reduce pain, inflammation, and changes of dermis thickness in the dorsal and ear skins, as well as the infiltration of mast cells in the skin of groups treated with DNCB. Moreover, MSC-CM, similar to betamethasone, decreased the level of IL-4 and MDA levels in the skin of DNCB receiving groups.</span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:"Calibri",sans-serif"><b><span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><span style="letter-spacing:-.2pt">Discussion & </span></span></span></span></b><b><span style="font-size:10.0pt"><span style="font-family:"Times New Roman",serif"><span style="letter-spacing:-.2pt">Conclusion:</span></span></span></b> <span style="font-size:9.0pt"><span style="font-family:"Times New Roman",serif">The increase in IL-4 levels and lipid peroxidation play an important role in inducing AD-like lesions in the skin of the mouse in the DNCB model; in addition, the topical application of the MSC-CM is a potential therapeutic agent for AD.</span></span></span></span></span><br>
درماتیت آتوپیک, دی نیترو کلروبنزن, محیط کشت غنیشده, سلول بنیادی مزانشیمی, اینترلوکین-4
Atopic dermatitis, Conditioned culture media, Dinitrochlorobenzene, Interleukin-4, Mesenchymal Stem Cells
32
44
http://sjimu.medilam.ac.ir/browse.php?a_code=A-10-3041-2&slc_lang=fa&sid=1
Zahra
Mohammadi
زهرا
محمدی
z.mohammadi.5731@gmail.com
9600319475328460046205
9600319475328460046205
No
Dept of Biology, School of Basic Sciences, Shahed University, Tehran, Iran
گروه زیستشناسی، دانشکدۀ علوم پایه، دانشگاه شاهد، تهران، ایران
Majid
Hassanpour-ezatti
مجید
حسن پورعزتی
hassanpour@shahed.ac.ir
9600319475328460046206
9600319475328460046206
Yes
Dept of Biology, School of Basic Sciences, Shahed University, Tehran, Iran
گروه زیستشناسی، دانشکدۀ علوم پایه، دانشگاه شاهد، تهران، ایران